Veriti Management LLC Genmab A/S Transaction History

Veriti Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$27.94 - $35.44 $187,449 - $237,766	-6,709 Reduced 42.59%	9,045 $287,000
Q3 2023 Oct 27, 2023	SELL	$35.27 - $42.24 $43,452 - $52,039	-1,232 Reduced 7.25%	15,754 $555,000
Q2 2023 Jul 13, 2023	BUY	$37.4 - $42.94 $18,999 - $21,813	508 Added 3.08%	16,986 $645,000
Q1 2023 Apr 26, 2023	BUY	$34.88 - $43.22 $38,054 - $47,153	1,091 Added 7.09%	16,478 $622,000
Q4 2022 Jan 20, 2023	BUY	$33.8 - $47.06 $21,530 - $29,977	637 Added 4.32%	15,387 $0
Q3 2022 Oct 26, 2022	BUY	$31.52 - $373.61 $122,518 - $1.45 Million	3,887 Added 35.78%	14,750 $474,000
Q2 2022 Jul 18, 2022	BUY	$26.83 - $38.57 $21,705 - $31,203	809 Added 8.05%	10,863 $353,000
Q1 2022 Apr 11, 2022	BUY	$30.95 - $39.68 $96,068 - $123,166	3,104 Added 44.66%	10,054 $364,000
Q4 2021 Jan 19, 2022	SELL	$35.87 - $47.12 $1,829 - $2,403	-51 Reduced 0.73%	6,950 $275,000
Q3 2021 Oct 08, 2021	BUY	$41.55 - $48.72 $30,663 - $35,955	738 Added 11.78%	7,001 $306,000
Q2 2021 Jul 13, 2021	BUY	$32.88 - $44.57 $205,927 - $279,141	6,263 New	6,263 $256,000
Q1 2021 Apr 14, 2021	SELL	$30.92 - $44.4 $32,033 - $45,998	-1,036 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$33.66 - $40.76 $34,871 - $42,227	1,036 New	1,036 $42,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Veriti Management LLC, based on Form 13F filings with the SEC.

Stay updated on Veriti Management LLC with notifications on news.